Thursday, January 27, 2022
WELCOME EDUCATIONAL DINNER BUFFET
19.00 Buffet opening
Friday, January 28, 2022
8.30-8.40 Opening
Heinz Ludwig and Jesús F. San-Miguel
MYELOMA BIOLOGY AND RISK STRATIFICATION
Moderator: Heinz Ludwig
8.40-9.00 Molecular events in the pathogenesis of myeloma
Niccolò Bolli
9.00-9.20 Epigenetic and environmental factors in the pathogenesis of MM
Charlotte Pawlyn
9.20-9.40 Genetic risk classification of multiple myeloma
Hervé Avet-Loiseau
9.40-10.10 Discussion around important questions
Discussants: Niccolò Bolli, Charlotte Pawlyn, Hervé Avet-Loiseau
• Role of genetic predisposition for MM
• Has the time come for a new classification of MM
• Has the time come for revision of risk factors
• Are epigenetic compounds underused
• Options for modulation of the immune environment
10.10-10.30 BREAK
NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT
Moderator: Jesús San-Miguel
10.30-10.50 The role of MRD
Bruno Paiva
10.50-11.10 Advances in imaging in MM including diffusion-weighted MRI
Martin Kaiser
11.10-11.30 Mass spectrometry for diagnosis and prognostication
Noemi Puig
11.30-12.00 Discussion around important questions
Discussants: Bruno Paiva, Martin Kaiser, Noemi Puig
• Requirements of regulatory agencies for approving MRD
• Circulating plasma cells for disease and response assessment
• Optimizing imaging technologies – MRI and PET/CT
• Impact of higher M-protein detection sensitivity (MGUS and MRD)
• MRD assessment and MGUS-like MM
WORKSHOPS
12.00-12.45 Detection, prevention and treatment of bone disease
Evangelos Terpos
12.00-12.45 Management of patients with solitary plasmacytoma, extramedullary myeloma and plasma cell leukemia
Kwee Yong
12.45- 13.45 LUNCH
MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE
Moderator: Heinz Ludwig
13.45-14.05 Smoldering MM. Present definition and approaches and a glance into the future
Maria-Victoria Mateos
14.05-14.25 Frontline therapy in TE patients
Philippe Moreau
14.25-14.45 Expanding opportunities for maintenance treatment
Michele Cavo
14.45-15.15 Discussion around important questions
Discussants: Maria-Victoria Mateos, Philippe Moreau, Michele Cavo
• Delaying ASCT yields similar survival as upfront ASCT. Why is this principle different in SMM
• Any ideas how to further improve prediction of progression to >90% within one year?
• What is the optimal number of induction and consolidation cycles?
• MRD guided therapy ready for prime time
• Maintenance therapy tomorrow
15.15-15.35 BREAK
MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS
Moderator: Jesús San-Miguel
15.35-15.55 Advances in the treatment of transplant-ineligible patients
Thierry Facon
15.55-16.15 Assessment of frailty and management of frail patients
Alessandra Larocca
16.15-16.45 Discussion of important questions
Discussants: Thierry Facon, Alessandra Larocca
• Initiation of therapy at biochemical progression
• Treatment duration
• Impact of individual risk on treatment selection
• Supportive care issues
• Treatment of very elderly patients
16.45-17.30 WORKSHOPS (repeated)
KEYNOTE LECTURE
Moderator: Heinz Ludwig
17.30-18.00 Cure is the goal: Progress in multiple myeloma
Jesús San-Miguel
Saturday, January 29, 2022
THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE
Moderator: Heinz Ludwig
8.30-8.50 How to select therapy after relapse to one or two prior treatment lines
Pieter Sonneveld
8.50-9.10 Hard to treat relapsed/refractory patients
Mohamad Mohty
9.10-9.30 Recently approved new drugs (Blenrep, Selinexor, Melflufen)
Fredrik Schjesvold
9.30-10.00 Discussion of important questions
Discussants: Pieter Sonneveld, Mohamad Mohty, Fredrik Schjesvold
• Early relapse
• Lenalidomide refractory patients
• CD38 retreatment
10.00-10.20 BREAK
HOT TOPICS IN MYELOMA
Moderator: Jesús San-Miguel
10.20-10.40 COVID in MM and associated diseases
Heinz Ludwig
10.40-11.00 BiTEs-and monoclonal antibodies
Niels van de Donk
11.00-11.20 CAR-T cells and other cellular therapies
Hermann Einsele
11.20-11.50 Discussion of important questions
Discussants: Heinz Ludwig, Niels van de Donk, Hermann Einsele
• Options for COVID vaccination in poor responders
• Improving tolerance of novel treatments
• BiTEs or cellular therapies
• Combination of novel drugs/treatment approaches
OTHER IMPORTANT DISEASES
Moderator: Heinz Ludwig
11.50-12.10 New developments in the management of Amyloidosis
Giampaolo Merlini
12.10-12.30 New developments in the management of Waldenström’s disease
Meletios A. Dimopoulos
12.30-12.45 Discussion of important questions
Discussants: Giampaolo Merlini, Melitios A. Dimopoulos
• Is cure a realistic goal in amyloidosis?
• Cellular therapies in amyloidosis
• Treatment of patients failing to first-line treatment with BTK inhibitors and CD 20-based therapies
• Should anti-BCMA treatments be explored in Waldenström’s disease as 2/3 express BCMA on their tumor clones?
12.45-12.50 Closure of the meeting
Jesús San-Miguel and Heinz Ludwig